Compte rendu du Cregg : les grands messages de l’année 2021 dans les MICI (notice n° 663504)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02741cam a2200289 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121193342.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Bazin, Thomas |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Compte rendu du Cregg : les grands messages de l’année 2021 dans les MICI |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 57 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Le SARS-CoV-2 n’est pas la seule actualité ! Dans les MICI (maladies inflammatoires chroniques intestinales), l’année 2021 a été riche en nouveautés. L’étude SEAVUE, bien que négative, semble montrer que l’ustékinumab est aussi efficace que l’adalimumab en première ligne dans la maladie de Crohn. L’étude STARDUST étudiant l’intérêt du treat-to-target sous ustékinumab est également négative, mais nous apprend surtout que le treat-to-target devient quasiment un « standard of care ». Bien sûr, les formes sous-cutanées de l’infliximab et du védolizumab sont là et vont profondément modifier notre pratique. Les aliments ultra-transformés n’ont décidément non seulement aucun intérêt, mais sont en plus associés à un sur-risque de développer une MICI ! Enfin, l’échographie continue à prouver, si besoin était encore, son intérêt dans le diagnostic et le suivi des MICI. Et n’oublions pas qu’un premier épisode de rectite est une IST jusqu’à preuve du contraire. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | SARS-CoV-2 is not the only news ! In IBD, the year 2021 has been rich in novelties. The SEAVUE study, although negative, appears to show that ustekinumab is as effective as adalimumab as first line treatment in Crohn’s disease. The STARDUST study studying the interest of treat-to-target under ustekinumab is also negative, but above all teaches us that treat-to-target is almost becoming a “standard of care”. Of course, the subcutaneous forms of infliximab and vedolizumab are there and will profoundly change our practice. Ultra-processed foods are definitely not only of no interest, but are also associated with an increased risk of developing IBD! Finally, ultrasound continues to prove, if needed, its value in the diagnosis and monitoring of IBD. And let’s not forget that a first episode of proctitis is an STI until proven otherwise. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | échographie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | sous-cutanée |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | treat-to-target |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ustékinumab |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | rectite |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | subcutaneous |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ustekinumab |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ultrasonography |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | proctitis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | treat to target |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 29 | 4 | 2022-04-01 | p. 523-529 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2022-4-page-523?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2022-4-page-523?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux